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The anti-inflammatory and cholesterol lowering capabilities of probiotic bacteria highlight
them as potential prophylactics against chronic inflammatory diseases, particularly
cardiovascular disease. Previous studies in silico, in vitro, and in vivo suggest that
the Lab4 probiotic consortium may harbour such capabilities and in the current
study, we assessed plasma levels of cytokines/chemokines, short chain fatty acids
and lipids and faecal levels of bile acids in a subpopulation of healthy Wistar rats
included in 90-day repeat dose oral toxicity study. In the rats receiving Lab4, circulating
levels of pro-inflammatory interleukin-6, tumour necrosis factor-α and keratinocyte
chemoattractant/growth regulated oncogene were significantly lower compared to
the control group demonstrating a systemic anti-inflammatory effect. These changes
occurred alongside significant reductions in plasma low density lipoprotein cholesterol
and increases in faecal bile acid excretion implying the ability to lower circulating
cholesterol via the deconjugation of intestinal bile acids. Correlative analysis identified
significant associations between plasma tumour necrosis factor-α and the plasma total
cholesterol:high density lipoprotein cholesterol ratio and faecal levels of bifidobacteria in
the Lab4 rats. Together, these data highlight Lab4 supplementation as a holistic approach
to CVD prevention and encourages further studies in humans.
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INTRODUCTION
The trillions of microorganisms residing in the human gut (the gut microbiota) are intrinsically
linked to the well-being of the host (1). Perturbations in the microbiota have been linked with a
range of diseases although it is often unclear if this is a causative factor or an epiphenomenon and
stabilization (2). The modulation of the gut microbiota by dietary means is being explored as a
means of preserving and rescuing health and attention is turning to the potential role for probiotic
organisms that are defined as “live microorganisms that, when administered in adequate amounts,
confer a health benefit on the host” (3).
Interest in the anti-inflammatory properties of probiotics is growing particularly due to the
potential benefits within the context of chronic inflammatory diseases (CID) where beneficial
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effects have been observed during rheumatoid arthritis,
inflammatory bowel disease and obesity (to name but a few)
(4, 5). A CID of particular concern is cardiovascular disease
(CVD) that is a progressive inflammatory disease of the
vasculature driven by hypercholesterolemia and is responsible
for more than 30% of all global mortalities (6). A recent meta-
analysis in high-risk subjects (with hypertension, excess body
weight or hypercholesterolemia) concluded that probiotics were
particularly effective for the reduction of low density lipoprotein-
cholesterol (LDL-C) (7). It is now understood that elevated
LDL-C can be a disease risk even in individuals with no history
of CVD or any of its comorbidities (8) and that even marginal
reductions in LDL-C profoundly lessen risk (9). Mechanistically,
the anti-inflammatory capabilities of probiotics has been
attributed to, at least in part, the generation of anti-inflammatory
short chain fatty acids (SCFA) such as acetate and butyrate (5).
The principle mechanism of cholesterol-lowering is related to
inherent bile salt hydrolase (BSH) enzymes that deconjugate
bile acids in the intestinal lumen rendering them less readily
reabsorbed for recycling in the liver (10). The deconjugated bile
acids are excreted from the body creating a bile acid deficit in the
host that is counteracted by increased hepatic bile synthesis that
utilises and therefore reduces circulatory cholesterol levels (11).
The Lab4 probiotic consortium comprises Bifidobacterium
bifidum, Bifidobacterium animalis subsp. lactis and two strains
of Lactobacillus acidophilus and anti-inflammatory capability has
been observed in a previous study where blood mononuclear
cells collected from Lab4 supplemented participants showed
impaired secretion of interleukin (IL)-6 and tumour necrosis
factor (TNF)-alpha ex vivo (12). Assessment in silico of genomic
composition identified genes encoding enzymes involved in the
generation of SCFAs in all Lab4 strains (13). The cholesterol-
lowering potential of Lab4 is better characterised and evidenced
by (i) the ability to reduce both circulating LDL-C levels and
bodyweight in hypercholesterolemic overweight and obese adults
(14) and (ii) ameliorate the impact of high fat diet (HFD)
induced elevations in plasma LDL-C and body weight in wild-
type C57BL/6J mice (15). In atherosclerosis prone mice receiving
a HFD, Lab4 contributed to the maintenance of plasma LDL-C
levels and the inhibition of atherosclerotic plaque (fatty deposit)
formation in the vasculature (16). All Lab4 organisms possess
the gene sequence encoding the BSH enzyme choloylglycine
hydrolase (13) and BSH activity has been observed during both
assessments in vitro and in vivo (17). Studies in vitro show
that the Lab4 consortium can assimilate cholesterol and regulate
cholesterol transport across the intestinal epithelium (17).
This study details the impact of Lab4 on traditional CVD
biomarkers (plasma cytokines/chemokines and lipids), plasma
SCFAs and faecal bile acid profiles following a 90-day repeat
feeding study in healthy wild-type Wistar rats.
MATERIALS AND METHODS
Animal Maintenance and Probiotic
Administration
The study was performed within the test facility of INTOX
Pvt. Ltd. (Maharashtra, India) in compliance with the OECD
Principles of Good Laboratory Practise [Organisation for
Economic Co-operation and Development (OECD), 1998]. The
animals in this study represent a subpopulation of a repeated dose
90-day oral toxicity study (13). Two groups of 10maleWistar rats
[6–7 weeks old, purchased from Vivo Bio Tech Ltd (Telangana,
India)] were housed in pathogen-free ventilated cages (2 rats
per cage) in a light- and temperature-controlled facility (12 h
light, 12 h dark, 19–25 ◦C) and received a daily gavage of either
the Lab4 probiotic comprising Lactobacillus acidophilus CUL21
(NCIMB 30156), Lactobacillus acidophilus CUL60 (NCIMB
30157), Bifidobacterium bifidum CUL20 (NCIMB 30153) and
Bifidobacterium animalis subsp. lactis CUL34 (NCIMB 30172)
at 3.0 x 1010 colony forming units (cfu) in 10mL phosphate
buffered saline (PBS, Lab4 group) or a placebo comprising
10mL sterile PBS (Control group) for 90 days. Throughout
the study, rats were given access ad libitum to a standard diet
[65 % carbohydrate, 24 % protein, 11 % fat (Altromin 1320,
Spezialfutter GmbH & Co. KG, Germany)] and sterilised water
in order to conform with animal welfare requirements. Body
weight and food consumption were monitored weekly. At the
end of the study, rats were sacrificed by exsanguination under
CO2 asphyxiation.
Blood Plasma Analysis
Overnight fasted blood was collected into heparinised tubes
at day 90. Plasma was extracted via centrifugation (1,000
x g, 5min) and stored at −80 ◦C pending further analysis.
Plasma concentrations of IL-4, IL-6, IL-10, IL-13, TNF-α,
interferon-γ (IFN-γ) and keratinocyte chemoattractant/growth
regulated oncogene (KC/GRO) were measured by the Central
Biotechnology Service (CBS; Cardiff University, UK) using the
VPLEX pro-inflammatory panel 1 rat kit (Meso Scale Discovery,
Maryland, USA). Total cholesterol (TC), high-density lipoprotein
cholesterol (HDL-C) and low-density lipoprotein cholesterol
(LDL-C) and triglyceride (TG) concentrations were measured
using Cholesterol and Triglyceride assay kits (ABCAM,
Cambridge, UK) in accordance with the manufacturer’s
instructions. Total plasma bile acid levels were measured using
the Xpand Plus Clinical Chemistry System (Siemens Healthcare
Diagnostics Inc. Newark, U.S.A.) in accordance with the
manufacturer’s instructions. SCFA were measured using targeted
gas chromatography and mass spectroscopy according to
Moreau et al. (18).
Faecal Bile Acid Analysis
Faecal samples collected at day 90 were measured for bile acid
content using ultra performance liquid chromatography-mass
spectrometry (UPLC-MS), as previously described (19). Faecal
pellets were lyophilized for 48 h (VirTis Benchtop BTP 8ZL
freeze dryer, BPS FUK), weighed and then homogenised in a
mixture of water, acetonitrile and 2-propanol (2:1:1 volumes)
using a Biospec bead beater with 1.0mm Zirconia beads. The
homogenates were centrifuged at 16,000 × g for 20min and
the supernatant filtered through a 0.45µm membrane (Costar,
Corning, UK). Bile acid analysis was performed on an ACQUITY
UPLC (Waters Ltd, Elstree, UK) coupled to a Xevo G2 Q-
ToF mass spectrometer equipped with an electrospray ionisation
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source operating in negative ionmode and bile acid standards [55
bile acid standards including 36 non-conjugated, 12 conjugated
with taurine, seven conjugated with glycine (Steraloids, Newport,
RI)] were used to determine the chromatographic retention
times. MassLynx software 4.1 was used for data acquisition.
Relative faecal bile acid intensities were normalised to the
faecal pellet dry weight. Principle component analysis (PCA)
was carried out using SIMCA v14.1.0.2047 (MKS Umetrics,
Umeå, Sweden) and heat-maps were generated in R package
(Version 3.1.3).
Analysis of Faecal Lactobacilli and
Bifidobacteria
Faecal samples were assessed for viable numbers of lactobacilli
and bifidobacteria during the study of Baker et al. (13). Briefly,
faeces were collected after 90 days intervention and 10-fold
dilution series were set up in Maximum Recovery Diluent
(MRD). Lactobacilli and bifidobacteria were plated on DeMan
Rogosa Sharpe (MRS) medium or MRSX [MRS containing
lithium chloride (1 g/L), sodium propionate (1.5 g/L) and L-
cysteine hydrochloride (0.25 g/L)] respectively and incubated
anaerobically (10 % carbon dioxide, 10 % hydrogen and 80 %
nitrogen) at 37 ◦C. Bacterial species was confirmed by Gram
staining, colony morphology and by analytical profile index
(API, BioMerieux, Marcy-l’Étoile, France). Viable counts were
recorded as the numbers of log10 colony forming units (cfus) per
gram of sample.
Statistical Analysis
All data are presented as mean ± standard deviation (SD)
of the assigned number of rats. All data were assessed for
homogeneity (Levene’s test) and normality (Shapiro-Wilk test
or inspection of Q-Q plots). For data that were non-normally
distributed, log or Box-Cox transformations were performed.
For single comparisons, values of p were determined using
an independent t-test (where data were normally distributed)
or Wilcoxon-Mann test for non-parametric data. For multiple
comparisons, values of pwere determined using one-way analysis
of variance (ANOVA) with Dunnett’s T3 post-hoc analysis or,
where data were not normally distributed after log or Box-
Cox transformation, Kruskal-Wallis followed by Dunn’s test
with Bonferroni correction. All statistical tests were performed
using GraphPad 7.0 (Prism). Where sufficient pairwise data was
available, correlations were performed with a Spearman’s rank
coefficient analysis in R package (Version 3.1.3). Differences were
considered significant when p < 0.05.
RESULTS
Plasma Inflammatory Markers
Supplementation with the Lab4 probiotic resulted in a significant
37.05 % reduction in plasma IL-6 (p = 0.026, Table 1A), a
significant 42.92 % reduction in TNF-α (p = 0.005) and a
significant 38.53 % reduction in KC/GRO (p = 0.036) compared
to levels in the control. No changes were observed for the other
inflammatory markers tested.
TABLE 1 | Plasma levels of inflammatory markers and lipids and faecal bile acid
content in male Wistar rats after 90 days supplementation with Lab4.
Control Lab4
A. Plasma inflammatory markers (pg/mL):
Interleukin-4 1.69 ± 0.09 1.67 ± 0.16
Interleukin-6 33.72 ± 6.03 21.23 ± 9.75*
Interleukin-10 9.27 ± 1.45 8.55 ± 2.05
Interleukin-13 5.71 ± 1.38 5.57 ± 0.71
Tumour necrosis factor-α 4.66 ± 1.76 2.66 ± 0.54**
Interferon-γ 1.90 ± 0.40 1.66 ± 0.27
Keratinocyte chemoattractant/growth
regulated oncogene
90.20 ± 38.75 55.46 ± 18.25*
B. Plasma lipids (mg/dL):
Total cholesterol (TC) 70.20 ± 12.15 68.90 ± 12.80
Low-density lipoprotein cholesterol
(LDL-C)
42.98 ± 8.04 33.18 ± 8.40*
High-density lipoprotein cholesterol
(HDL-C)
22.70 ± 7.80 32.85 ± 10.67 p=0.063
Triglycerides 60.11 ± 11.21 72.78 ± 18.03
TC:HDL-C ratio 3.71 ± 1.66 2.11 ± 0.59*
LDL-C:HDL-C ratio 2.26 ± 1.29 0.50 ± 0.23**
C. Faecal bile acid content (as a ratio of control group):
Total bile acids NA 1.14 ± 0.18 p=0.063
Conjugated bile acids NA 0.97 ± 0.41
Unconjugated bile acids NA 1.14 ± 0.19 p=0.052
Conjugate/Unconjugated ratio NA 0.86 ± 0.38
Cholic acid NA 1.60 ± 0.40*
Data represents the mean ± SD of 6 to 10 rats per group (A) or 10 rats per group (B and
C). Values of p were *p < 0.05 or **p < 0.05 or as stated compared to the control group.
NA, not applicable.
Plasma SCFA
Plasma SCFA concentrations were comparable between groups
(Figure 1) although levels in the Lab4 group were consistently
higher than in the control group: valeric acid (0.56 ± 0.21 vs.
0.38 ± 0.34 pg/ml respectively, 47.4 % increase), acetic acid
(14.04± 5.64 vs. 9.56± 4.74 pg/ml respectively, 46.9 % increase),
isobutyric acid (1.46 ± 0.51 vs. 1.16 ± 0.46 pg/ml respectively,
25.9 % increase), butyric acid (1.65 ± 0.52 vs. 1.36 ± 0.50 pg/ml
respectively, 21.3 % increase), isovaleric acid (0.16 ± 0.04 vs.
0.15 ± 0.59 pg/ml respectively, 6.7 % increase) and propionic
acid (18.59 ± 4.57 vs. 18.31 ± 7.68 pg/ml respectively, 1.5
% increase).
Plasma Lipids
Plasma total cholesterol (TC) and triglycerides (TG) were
similar between groups after 90 days feeding. LDL-C was
significantly lower (−22.8 %, p = 0.029, Table 1B) and HDL-
C was higher (44.7 %, p = 0.063) in the Lab4 group
compared to the control. Between group ratios of LDL-C:HDL-
C (−50.4 %, p = 0.007) and TC:HDL-C (−36.8 %, p =
0.028) were significantly lower for the Lab4 group. Bodyweights
and food consumption rates did not differ between groups
(Supplementary Figure S1).
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FIGURE 1 | Plasma levels of SCFA in Wistar rats after 90 days supplementation. Plasma levels of SCFA were quantified in control or Lab4 supplemented rats. Data
represent the means ± SD of six to eight rats per group. SCFA, short chain fatty acid.
FIGURE 2 | Faecal bile acid profiles of Wistar rats after 90 days supplementation. (A) Principle component analysis (PCA) scores plot of bile acid signatures from
control or Lab4 supplemented rats or (B) heat-map of the bile acid relative intensity for each rat. Analysis was performed on 10 rats per group.
Faecal Bile Acid Profiling
No significant differences were observed between groups in
the faecal bile acid profiles whether by Principle Component
Analysis (PCA; Figure 2A) or heat-map analysis (Figure 2B)
but a more variable spatial organisation was observed for
the Lab4 group (Figure 2A). Univariate analysis detected
14 % higher levels of both total and unconjugated bile
acids (p = 0.063 and p = 0.052, respectively, Table 1C)
and 60 % higher levels of cholic acid (p = 0.043) in the
Lab4 group compared to the control. No further significant
differences were observed (Supplementary Figure S2) and total
bile concentrations in blood plasma were consistent between
groups (data not shown).
Spearman’s Ranked Correlation Analysis
Correlative analysis was performed for plasma
cytokines/chemokines, plasma SCFAs, plasma lipids, faecal
bile acids and faecal numbers of viable lactobacilli and
bifidobacteria [measured by Baker et al. (13), data shown in
Supplementary Figure S3]. TNF-α levels correlated negatively
with faecal levels of Bifidobacterium (R = −0.94, p = 0.0048,
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FIGURE 3 | Correlative analysis in Wistar rats after 90 days supplementation
with Lab4. Scatter plots between plasma tumour necrosis factor-α (TNF-α)
levels and (A) faecal Bifidobacterium levels or (B) the plasma TC:HDL-C ratio
in rats receiving Lab4 for 90 days. Analysis was performed on pairwise data
from six rats. TNF, tumour necrosis factor; TC, total cholesterol; HDL-C, high
density lipoprotein cholesterol.
Figure 3A) and positively with plasma TC:HDL-C (R = 0.89, p
= 0.019, Figure 3B) only in the Lab4 group.
DISCUSSION
During this 90-day feeding study in wild-type Wistar rats, daily
supplementation with the Lab4 probiotic imparted an anti-
inflammatory effect by reducing plasma levels of IL-6, TNF-α and
KC/GRO and improved plasma cholesterol profiles, possibly via
the enhancement of bile acid deconjugation in the intestines.
Elevated levels of pro-inflammatory cytokines have been
detected in healthy asymptomatic individuals and are thought
to be triggered by many factors including stress, poor diet,
physical inactivity and lack of sleep (20). Plasma analysis of
the Lab4 supplemented rats revealed significant reductions
in the pro-inflammatory cytokines IL-6 and TNF-α and
the pro-inflammatory chemokine KC/GRO implying an anti-
inflammatory capability. These findings align with the outcomes
from a previous study where analysis ex vivo of blood
mononuclear cells collected from Lab4 supplemented healthy
adult participants showed reduced secretion of IL-6 and TNF-α
(12). Other probiotic studies have demonstrated the ability
of bifidobacteria and/or lactobacilli to reduce plasma levels
of IL-6 and/or TNF-α in pre-clinical animal models (21–
23) and human subjects (24) and Lactobacillus fermentum
JDFM216 supplementation reduced serum KC/GRO in ageing
mice (25). Inflammation is a major risk factor of CVD and
a myriad of pro-inflammatory cytokines and chemokines have
been associated with this disease progression (26). IL-6 and
TNF-α are predominantly produced by cells of the innate
immune system including monocytes, macrophages and natural
killer cells in response to a physiological challenge (e.g.,
oxidative stress) (27). Pharmacological inhibition of their activity
is considered a promising approach to reduce CVD risk
(28, 29).
The anti-inflammatory capabilities of probiotics have been
linked, at least in part, with the generation of SCFAs such
as acetic, propionic and butyric acid, via the fermentation of
dietary fibre (30). In rats receiving Lab4, a general pattern
of increase was observed for each SCFA measured with
notable changes occurring for valeric, acetic and butyric acids.
Each strain of the Lab4 consortium possesses gene sequences
encoding phosphate acetyltransferase and acetate kinase that
are involved in the generation of acetate (31): acetate is
recognised as an anti-inflammatory SCFA known to inhibit
the expression of IL-6 by colon cells (32). The recent study
of Yang et al. showed that administration of Lactobacillus
fermentum ZJUIDS06 increased levels of acetic, propionic and
butyric acid in the colons of hypercholesterolemic hamsters
whilst significantly reducing plasma cholesterol levels (33). SCFA
are known to have pleiotropic effects on the host and there
is growing evidence supporting beneficial effects on cholesterol
metabolism (34).
Hypercholesterolemia is a major risk factor for CVD (35) and
reductions in circulating cholesterol levels, particularly LDL-C,
are encouraged to reduce the risk of CVD (36) even in overtly
healthy subjects (8). In this study with Lab4 supplemented rats we
showed a 22.8% reduction in the plasma LDL-C concentration
even in the absence of any hypercholesteraemic profile. Such
outcomes could imply a potential cardiovascular benefit and
expand on the outcomes of our own studies with Lab4 (13, 14,
16, 17) whilst adding to the growing evidence supporting an
LDL-C lowering capability by probiotics (7). In contrast, due
to their function in the disposal of excess cholesterol via the
liver, high circulating HDL-C levels are linked to a reduced CVD
risk (37). In the probiotic fed rats, plasma HDL-C levels were
44 % higher than in the control group – an outcome consistent
with findings observed in a study with Lab4 supplemented
atherosclerosis prone mice (16). In both studies, the changes in
lipid profiles contributed to significant reductions in the TC:HDL
and LDL:HDL ratios in the animals receiving Lab4 compared
to the controls. The TC:HDL and LDL:HDL ratios are clinically
recognised markers of cardiovascular risk (37).
Reduction of cholesterol by probiotic bacteria can involve
the deconjugation of bile acids in the intestinal lumen
which is mediated by the actions of inherent BSH enzymes
(11). The Lab4 consortium has BSH activity (13, 17) and
increased excretion rates of deconjugated bile acids (both
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total and cholic) were seen with Lab4 treated Wistar rats
indicating an ability to impact upon bile acid metabolism
during normal metabolic processes and consistent with the
reductions observed in circulating LDL-C. The ability of Lab4
to assimilate cholesterol and regulate the transport of cholesterol
across the intestinal epithelium (17) may have contributed to
its hypocholesterolaemic effects and represents a avenue of
future research.
Correlative analyses showed that plasma levels of TNF-α
were negatively associated with numbers of faecal bifidobacteria
in the Lab4 supplemented rats. As previously mentioned,
anti-inflammatory activity is recognised in bifidobacteria (38),
the Lab4 consortium comprises Bifidobacterium bifidum and
Bifidobacterium animalis subsp. lactis and increased levels of
viable bifidobacteria (and lactobacilli) were observed in the
faeces of the rats receiving Lab4 (Supplementary Figure S3).
In addition, TNF-α levels positively correlated with the plasma
TC:HDL-C ratio potentially linking circulating TNF-α and CVD
development (39).
There are a number of limitations of the study. Only healthy
male rats receiving a single dose of probiotic were included
in the analysis. Future studies should assess the cardiovascular
and inflammatory impact of different doses of Lab4 in healthy
male and female subjects and in cohorts with high risk of
cardiovascular disease.
In summary, 90-day supplementation of rats with the Lab4
probiotic resulted in significant reductions in circulating levels
of IL-6, TNF-α and KC/GRO and improvements in circulating
lipid profiles, possibly mediated by the increased excretion of
bile acids. This study highlights daily supplementation with the
Lab4 consortium as a potential prophylactic against CVD and has
provided support for future human intervention studies.
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